These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 16430195

  • 1. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L, Treanor J, Gubareva L, Hayden FG.
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [Abstract] [Full Text] [Related]

  • 2. Intravenous peramivir for treatment of influenza in hospitalized patients.
    Ison MG, Fraiz J, Heller B, Jauregui L, Mills G, O'Riordan W, O'Neil B, Playford EG, Rolf JD, Sada-Diaz E, Elder J, Collis P, Hernandez JE, Sheridan WP.
    Antivir Ther; 2014; 19(4):349-61. PubMed ID: 23985625
    [Abstract] [Full Text] [Related]

  • 3. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE.
    JAMA; 1999 Oct 06; 282(13):1240-6. PubMed ID: 10517426
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Peramivir for the treatment of influenza.
    Shetty AK, Peek LA.
    Expert Rev Anti Infect Ther; 2012 Feb 06; 10(2):123-43. PubMed ID: 22339187
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA.
    Lancet Infect Dis; 2014 Feb 06; 14(2):109-18. PubMed ID: 24268590
    [Abstract] [Full Text] [Related]

  • 7. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors.
    Komeda T, Ishii S, Itoh Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2016 Oct 06; 22(10):677-84. PubMed ID: 27497712
    [Abstract] [Full Text] [Related]

  • 8. A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults.
    Ison MG, Hui DS, Clezy K, O'Neil BJ, Flynt A, Collis PJ, Simon TJ, Alexander WJ.
    Antivir Ther; 2013 Oct 06; 18(5):651-61. PubMed ID: 23111657
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.
    Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S, Watanabe M, Hashimoto K, Miyazaki K, Kawasaki Y, Hosoya M.
    Antimicrob Agents Chemother; 2015 Mar 06; 59(3):1643-9. PubMed ID: 25547357
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Efficacy of Intravenous Peramivir and Oral Oseltamivir for the Treatment of Influenza: Systematic Review and Meta-Analysis.
    Lee J, Park JH, Jwa H, Kim YH.
    Yonsei Med J; 2017 Jul 06; 58(4):778-785. PubMed ID: 28540991
    [Abstract] [Full Text] [Related]

  • 15. Peramivir: A Review in Uncomplicated Influenza.
    Scott LJ.
    Drugs; 2018 Sep 06; 78(13):1363-1370. PubMed ID: 30196350
    [Abstract] [Full Text] [Related]

  • 16. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
    Harada N, Shibata W, Koh H, Takashita E, Fujisaki S, Okamura H, Nanno S, Yamada K, Nakamae H, Hino M, Kakeya H.
    BMC Infect Dis; 2020 Jul 06; 20(1):478. PubMed ID: 32631240
    [Abstract] [Full Text] [Related]

  • 17. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.
    Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J, S-021812 Clinical Study Group.
    Antimicrob Agents Chemother; 2011 Jun 06; 55(6):2803-12. PubMed ID: 21464252
    [Abstract] [Full Text] [Related]

  • 18. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation.
    Komeda T, Ishii S, Itoh Y, Ariyasu Y, Sanekata M, Yoshikawa T, Shimada J.
    J Infect Chemother; 2014 Nov 06; 20(11):689-95. PubMed ID: 25131292
    [Abstract] [Full Text] [Related]

  • 19. Peramivir: an intravenous neuraminidase inhibitor.
    McLaughlin MM, Skoglund EW, Ison MG.
    Expert Opin Pharmacother; 2015 Nov 06; 16(12):1889-900. PubMed ID: 26153242
    [Abstract] [Full Text] [Related]

  • 20. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
    Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG.
    N Engl J Med; 1999 Oct 28; 341(18):1336-43. PubMed ID: 10536125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.